[go: up one dir, main page]

WO2004010973A3 - Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage - Google Patents

Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage Download PDF

Info

Publication number
WO2004010973A3
WO2004010973A3 PCT/US2003/024043 US0324043W WO2004010973A3 WO 2004010973 A3 WO2004010973 A3 WO 2004010973A3 US 0324043 W US0324043 W US 0324043W WO 2004010973 A3 WO2004010973 A3 WO 2004010973A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
storage
pharmaceutical dosage
dissolution profile
form capable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/024043
Other languages
French (fr)
Other versions
WO2004010973A2 (en
Inventor
Ping Gao
Juliane M Bauer
Xiaorong He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to MXPA05000862A priority Critical patent/MXPA05000862A/en
Priority to CA002494358A priority patent/CA2494358A1/en
Priority to AU2003257982A priority patent/AU2003257982A1/en
Priority to BR0313149-1A priority patent/BR0313149A/en
Priority to EP03772160A priority patent/EP1526845A2/en
Priority to JP2004524262A priority patent/JP2005538994A/en
Publication of WO2004010973A2 publication Critical patent/WO2004010973A2/en
Publication of WO2004010973A3 publication Critical patent/WO2004010973A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)

Abstract

The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a primary or secondary amine compound in an amount sufficient to inhibit cross-linking of gelatin in said gelatin capsule upon storage of the dosage form in a closed container maintained at 40 °C and 75 % relative humidity for a period of 6 months.
PCT/US2003/024043 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage Ceased WO2004010973A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA05000862A MXPA05000862A (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage.
CA002494358A CA2494358A1 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
AU2003257982A AU2003257982A1 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
BR0313149-1A BR0313149A (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of stable dissolution profile after storage
EP03772160A EP1526845A2 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
JP2004524262A JP2005538994A (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of maintaining a stable dissolution profile in storage

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US39986202P 2002-07-31 2002-07-31
US39986302P 2002-07-31 2002-07-31
US39977602P 2002-07-31 2002-07-31
US39980802P 2002-07-31 2002-07-31
US60/399,862 2002-07-31
US60/399,776 2002-07-31
US60/399,863 2002-07-31
US60/399,808 2002-07-31

Publications (2)

Publication Number Publication Date
WO2004010973A2 WO2004010973A2 (en) 2004-02-05
WO2004010973A3 true WO2004010973A3 (en) 2004-08-05

Family

ID=31192378

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2003/024042 Ceased WO2004010972A2 (en) 2002-07-31 2003-07-31 Pellicle-resistant gelatin capsule
PCT/US2003/024045 Ceased WO2004010974A2 (en) 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking
PCT/US2003/024043 Ceased WO2004010973A2 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
PCT/US2003/024044 Ceased WO2004022032A2 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form comprising a sulfite compound

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2003/024042 Ceased WO2004010972A2 (en) 2002-07-31 2003-07-31 Pellicle-resistant gelatin capsule
PCT/US2003/024045 Ceased WO2004010974A2 (en) 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024044 Ceased WO2004022032A2 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form comprising a sulfite compound

Country Status (7)

Country Link
EP (4) EP1526846A2 (en)
JP (4) JP2005538102A (en)
AU (4) AU2003257102A1 (en)
BR (4) BR0313150A (en)
CA (4) CA2493980A1 (en)
MX (4) MXPA05000862A (en)
WO (4) WO2004010972A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103582A2 (en) 2002-06-05 2003-12-18 Ivax Corporation Reduction of gelatin cross-linking
CN101142198B (en) 2005-02-17 2012-10-31 辛塔制药公司 Isoxazole cambrestatin derivatives for use in the treatment of diseases
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
ATE485033T1 (en) * 2005-07-26 2010-11-15 Nicox Sa PHARMACEUTICAL FORMULATION OF NITROOXY DERIVATIVES OF NSAIDS
JP5503939B2 (en) * 2009-10-16 2014-05-28 東洋カプセル株式会社 Azelastine hydrochloride-containing capsule
JP6887456B2 (en) 2018-07-04 2021-06-16 キャプシュゲル・ベルジウム・エヌ・ヴィ A film-forming composition containing a surfactant or a surfactant and a salt as a whitening agent.
US11364478B2 (en) * 2019-05-22 2022-06-21 Mezzimatic, LLC Method of manufacturing throwable paintballs and paintballs made therefrom
KR20220077091A (en) * 2020-12-01 2022-06-08 주식회사 엘지화학 Composite formulation for oral administration comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxyl acid and a process for the preparation thereof
CN113230241A (en) * 2021-06-11 2021-08-10 北京畅盛医药科技有限公司 Application of tris (hydroxymethyl) aminomethane salt in medicine for treating cardiovascular and cerebrovascular diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204401A1 (en) * 1972-11-01 1974-05-24 Meiji Seika Co
FR2617047A1 (en) * 1987-06-23 1988-12-30 Sanofi Sa Gelatin composition which withstands tanning, capsules based on this composition and their pharmaceutical application, in particular to fenofibrate
JPH0334921A (en) * 1989-06-30 1991-02-14 Teikoku Hormone Mfg Co Ltd gelatin capsules
EP0679395A1 (en) * 1994-04-26 1995-11-02 Bayer S.p.A. Pharmaceutical compositions containing a ketoprofen solution in a soft gelatine capsule and method to produce them
EP0695544A1 (en) * 1994-08-05 1996-02-07 Shionogi & Co., Ltd. Hard gelatin capsules resistant to denaturation and the production thereof
WO2002056878A2 (en) * 2001-01-18 2002-07-25 Pharmacia Corporation Pharmaceutical composition having reduced tendency for drug crystallization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349529A (en) * 1980-04-14 1982-09-14 E. R. Squibb & Sons, Inc. Diagnostic and therapeutic capsules and method of producing
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
KR100338851B1 (en) * 1994-03-15 2002-10-12 센주 세이야꾸 가부시키가이샤 How to stabilize pranopropene and stable pranopropene
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204401A1 (en) * 1972-11-01 1974-05-24 Meiji Seika Co
FR2617047A1 (en) * 1987-06-23 1988-12-30 Sanofi Sa Gelatin composition which withstands tanning, capsules based on this composition and their pharmaceutical application, in particular to fenofibrate
JPH0334921A (en) * 1989-06-30 1991-02-14 Teikoku Hormone Mfg Co Ltd gelatin capsules
EP0679395A1 (en) * 1994-04-26 1995-11-02 Bayer S.p.A. Pharmaceutical compositions containing a ketoprofen solution in a soft gelatine capsule and method to produce them
EP0695544A1 (en) * 1994-08-05 1996-02-07 Shionogi & Co., Ltd. Hard gelatin capsules resistant to denaturation and the production thereof
WO2002056878A2 (en) * 2001-01-18 2002-07-25 Pharmacia Corporation Pharmaceutical composition having reduced tendency for drug crystallization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 0151, no. 63 (C - 0826) 24 April 1991 (1991-04-24) *

Also Published As

Publication number Publication date
AU2003257981A8 (en) 2004-02-16
JP2005538993A (en) 2005-12-22
WO2004010972A3 (en) 2004-07-29
WO2004022032A3 (en) 2004-08-12
AU2003257102A8 (en) 2004-03-29
AU2003257982A8 (en) 2004-02-16
CA2494358A1 (en) 2004-02-05
AU2003257102A1 (en) 2004-03-29
JP2006500389A (en) 2006-01-05
AU2003257981A1 (en) 2004-02-16
JP2005538994A (en) 2005-12-22
BR0313064A (en) 2005-06-28
BR0313150A (en) 2005-06-28
WO2004022032A2 (en) 2004-03-18
MXPA05001166A (en) 2005-05-16
EP1526844A2 (en) 2005-05-04
AU2003257103A8 (en) 2004-02-16
WO2004010972A2 (en) 2004-02-05
EP1526846A2 (en) 2005-05-04
EP1526845A2 (en) 2005-05-04
JP2005538102A (en) 2005-12-15
MXPA05001272A (en) 2005-04-28
WO2004010973A2 (en) 2004-02-05
BR0312875A (en) 2005-06-28
CA2494069A1 (en) 2004-02-05
WO2004010974A2 (en) 2004-02-05
WO2004010974A3 (en) 2004-08-05
CA2493980A1 (en) 2004-02-05
BR0313149A (en) 2005-06-28
EP1526847A2 (en) 2005-05-04
MXPA05001167A (en) 2005-05-16
AU2003257103A1 (en) 2004-02-16
AU2003257982A1 (en) 2004-02-16
MXPA05000862A (en) 2005-04-19
CA2493974A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
SI2395002T1 (en) Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters.
IL164798A0 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
IS4326A (en) New storage granules and pharmaceutical compositions containing them
IL170690A0 (en) Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
ATE310508T1 (en) DOSAGE FORM CONTAINING THERAPEUTIC FORMULATION
EP1619180A4 (en) CaSR ANTAGONIST
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
WO2001041737A3 (en) Solid oral dosage form
PL393385A1 (en) Method for modification and habit recrystallization of drug substance, mycophenolate sodium crystals, the use thereof and pharmaceutical composition
UA87180C2 (en) film container or packaging
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
WO2004010973A3 (en) Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
WO2005007137A8 (en) Tablets containing ambroxol
NO20060852L (en) Pharmaceutical preparations
WO2007075475A3 (en) Gastric reflux resistant dosage forms
EE200100104A (en) A novel oral dosage form of a 5-HT4 agonist or antagonist
AU2003227051A1 (en) Pack for medicine in capsule, pill or similar form
ATE491341T1 (en) EDIBLE, DISSOLVING GELATIN STRIPS
WO2004062552A3 (en) Pharmaceutical composition containing a nsaid and a benzimidazole derivative
WO2006040779A3 (en) Controlled release gastric floating matrix formulation containing imatinib
WO2004043356A3 (en) Coated dibasic calcium phosphate
TR200601092T1 (en) New oral pharmaceutical formulations containing the active ingredient irbesartan.
GEP20043377B (en) Pharmaceutical Complex
MY141008A (en) Oral formulations of deoxypeganine and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/000862

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2494358

Country of ref document: CA

Ref document number: 2003772160

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004524262

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003772160

Country of ref document: EP